Discovery of ((4-(5-(Cyclopropylcarbamoyl)-2-methylphenylamino)-5-methylpyrrolo[1,2-f][1,2,4]triazine-6-carbonyl)(propyl)carbamoyloxy)methyl-2-(4-(phosphonooxy)phenyl)acetate (BMS-751324), a Clinical Prodrug of p38α MAP Kinase Inhibitor
Chunjian Liu, James Lin, John Hynes, Hong Wu, Stephen T. Wrobleski, Shuqun Lin, T. G.Murali Dhar, Vivekananda M. Vrudhula, Jung Hui Sun, Sam Chao, Rulin Zhao, Bei Wang, Bang Chi Chen, Gerry Everlof, Christoph Gesenberg, Hongjian Zhang, Punit H. Marathe, Kim W. McIntyre, Tracy L. Taylor, Kathleen GilloolyDavid J. Shuster, Murray McKinnon, John H. Dodd, Joel C. Barrish, Gary L. Schieven, Katerina Leftheris
Dive into the research topics of 'Discovery of ((4-(5-(Cyclopropylcarbamoyl)-2-methylphenylamino)-5-methylpyrrolo[1,2-f][1,2,4]triazine-6-carbonyl)(propyl)carbamoyloxy)methyl-2-(4-(phosphonooxy)phenyl)acetate (BMS-751324), a Clinical Prodrug of p38α MAP Kinase Inhibitor'. Together they form a unique fingerprint.